Patents by Inventor Catia Traversari

Catia Traversari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
    Patent number: 5837476
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: November 17, 1998
    Assignee: Ludwig Institute
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules
    Patent number: 5695994
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by HLA molecules HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: December 9, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5620886
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 18, 1993
    Date of Patent: April 15, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas W olfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 5554506
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: September 10, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pierre van der Bruggen, Thierry Boon-Falleur, Catia Traversari, Katharina Fleischauer
  • Isolated nucleic acid molecules which encode MAGE derived nonapeptides
    Patent number: 5462871
    Abstract: The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: October 31, 1995
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Isolated nonapeptides derived from MAGE genes and uses thereof
    Patent number: 5405940
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: April 11, 1995
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
    Patent number: 5342774
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: August 30, 1994
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari